Clinical Trials

IMPACT

Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)

Adult subject inclusion criteria:

• Age: At least 18 years of age
• Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
• Tumor must have a supratentorial component 
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening

Pediatric subject inclusion criteria:

• Ages four to >18 years old
• Newly-diagnosed pHGG based on the absence of previous history of brain tumor (WHO Grade III-IV glioma) by histopathology
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening

See full inclusion criteria and learn more about the IMPACT Clinical Trial.

Contact Phuong Deleyrolle for more info:
-Email: Wells-btc@ufl.edu

PNOC020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Please note:

• Surgical resection is required to be performed at UF.  
• Enrollment must occur in person at UF prior to surgery or any treatment modalities

Adult subject inclusion criteria:

• Age: 21 Years and older (Adult, Older Adult)
• Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
• The tumor must have a supratentorial component.
• Bone Marrow, Renal and Hepatic tests

Pediatric subject inclusion criteria:

• > 3 years
• No Methylation requirement
• The Tumor must have a supratentorial component.
• Bone Marrow, Renal, and Hepatic tests

See full inclusion criteria and learn more about the PNOC020 Clinical Trial

Contact Marcia Hodik for more info:
-Email: Wells-btc@ufl.edu